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India’s strong commitment and capacity to ad-
dress the HIV epidemic contributed to a more 
than 50 percent decline in new HIV infections 
from 2000 to 2009 (UNAIDS 2012). The initial 
response focused on awareness generation 
and preventing HIV acquisition in the general 
population. As data and experience led to 
a deeper understanding of the epidemic, a 
targeted approach has emphasised containing 
HIV transmission from high-risk groups to the 
general population. Importantly, India has also 
provided a growing programme of treatment 
and care for people living with HIV. 
Globally and in India, women face significant 
social and economic vulnerability to HIV. Cur-
rently, women constitute more than one-third 
(39 percent) of the HIV-positive population in 
India (NIMS/NACO 2012), and many more are 
vulnerable to acquiring HIV and other sexually 
transmitted infections (STIs). Overall women 
have lower social status than men, and many 
women have little or no capacity to control or 
make decisions about their sexual lives. Men’s 
risk-taking behaviour increases women’s HIV 
risk. 
An effective female-controlled HIV-prevention 
method could mitigate women’s risk. Renewed 
interest and new designs for female condoms 
are slowly improving access; efforts in India 
are focused primarily on female sex workers. 
Vaginal microbicides are another potential tool 
that women could use to protect themselves 
from HIV acquisition, and research to identify 
an effective microbicide continues. 
Indian researchers have actively collaborated 
in global efforts to find an effective vaginal 
microbicide, and clinical trials for several 
candidate products have included sites in India 
(Joshi et al. 2005; Joglekar et al. 2007; Van 
Damme et al. 2008; Mehendale et al. 2012). 
Tenofovir gel is the only candidate microbi-
cide that has been shown to be effective in a 
clinical trial, although results from tenofovir gel 
trials have been mixed. The CAPRISA 004 trial 
in South Africa showed a 39 percent reduction 
in women’s risk of HIV infection compared 
with a placebo, providing the first clinical 
evidence that a vaginal gel can be effective in 
HIV prevention (Abdool Karim 2010). Women 
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in the CAPRISA trial were counseled to use the gel before 
and after sex. The VOICE trial tested daily tenofovir in 
both oral pill and vaginal gel forms, as well as daily oral 
Truvada; none of these three products showed an effect 
in reducing the risk of HIV acquisition, likely due to low 
adherence. (Marrazzo, et al. 2013). FACTS 001, a large-
scale trial under way in South Africa, is replicating the 
same dosing strategy for tenofovir gel that was used in 
the CAPRISA 004 trial. The results from the FACTS trial 
will provide a clearer picture of tenofovir gel effective-
ness. 
Background on this Brief 
Given the urgent need for HIV-prevention options for 
women, a number of efforts are underway to prepare for 
introduction of tenofovir gel should it be shown effec-
tive. One of these is a Guide to assist policymakers and 
programme managers in identifying the most strategic 
opportunities for introducing tenofovir gel. The Guide 
includes three related components: a landscape analy-
sis; a discussion guide for key opinion leader interviews; 
and a programme planning tool. The landscape analysis, 
summarised in this programme brief, 
reviews the epidemiologic context of 
the HIV epidemic, highlights key poli-
cies and programmes related to HIV, 
and provides other information rele-
vant to potential introduction of teno-
fovir vaginal gel in India. It draws on a 
desk review of peer-reviewed and grey 
literature as well as interviews with key 
decision-makers (Prabhughate, et al. 
2014). The full report and annexes are 
available at www.popcouncil.org.
The policy and programme review sum-
marised here underscores a generally 
favorable environment for introducing 
tenofovir gel in India, although the 
costs and benefits of such an effort 
would need further consideration. 
India has long been an early adopter 
of innovations in health as well as in 
other sectors. It has a robust and growing pharmaceutical 
industry known for low-cost drug production and, increas-
ingly, for research and development of new drugs. At the 
same time the overall direction of HIV programming to-
ward comprehensive prevention and integrated services 
suggests that tenofovir gel could potentially be incorporat-
ed into the health system and provided to different user 
groups. 
The HIV Epidemic in India
The 2011 national sentinel surveillance estimated that 
1.9 million people in India aged 15 and older were living 
with HIV (NIMS/NACO 2012). An estimated 39 percent 
are women. This represents a decline in the total number 
of people living with HIV (PLHIV) and prevalence of HIV in 
the country (see Figure 1) (NACO 2012). This decline has 
varied across states. Although HIV prevalence declined in 
six high-prevalence states1 from 2007–2011, it increased 
in 11 other states (NIMS/NACO 2012).2 Along with declin-
ing prevalence overall, there was also a downward trend 
in incidence and AIDS-related deaths from 2000–2009 
(see Figure 2). In 2011, there was a further marginal 
decline in new infections (1.16 million) and AIDS-related 
deaths (1.5 million) (NIMS/NACO 2012). The reduction in 
deaths has been attributed to free antiretroviral treat-
ment (ART) made available since 2004 (NACO 2012).
1States where HIV prevalence declined between 2007 and 2011: 
Andhra Pradesh, Karnataka, Maharashtra, Manipur, Nagaland, and 
Tamil Nadu. 
2States where HIV prevalence increased between 2007 and 2011: 
Arunanachal Pradesh, Assam, Chandigarh, Chattisgarh, Delhi, Jammu 
and Kashmir, Jharkhand, Kerala, Odisha, Punjab, Tripura, and Uttara-
khand.
 
Figure 1  Trend of HIV prevalence in India (2004–2009)
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The main route of HIV transmission is unprotected sex 
(87.4 percent heterosexual and 1.3 percent homosexual), 
except in northeastern states where injection drug use 
is the predominant route of transmission (NACO 2011a). 
The epidemic is concentrated, as prevalence remains 
high among specific high-risk groups (now often referred 
to as most-at-risk populations), which include injection 
drug users, men who have sex with men, and female sex 
workers, and bridge populations of male migrants and 
truckers (see Figure 3) (NACO 2012). 
In 2009, prevalence among high-risk 
groups was much higher than the 
national prevalence—9.2 percent in 
injection drug users, 7.3 percent in 
men who have sex with men, and 4.9 
percent in female sex workers (UNAIDS 
2010). 
In response, the National AIDS Control 
Programme-III (NACP-III, 2007–2012) 
emphasised targeted interventions for 
prevention focused on high-risk groups 
and bridge populations. These were 
peer-led interventions implemented 
through nongovernmental organiza-
tions (NGOs) and community-based 
organizations (CBOs) supported and 
monitored by government agencies. 
Women’s Vulnerabilities and 
Risks
A variety of social and economic vul-
nerabilities place women at risk of HIV. 
Female sex workers’ particular vulnera-
bilities are recognised in the NACP, with 
concomitant programme responses. 
While the NACP now identifies women 
as a vulnerable population, many other 
risk factors specific to women are not 
addressed in the programme. These 
include: young age at marriage; male 
migration; men who have sex with 
men and women; and intimate partner 
violence. 
Age at marriage. Many women in India 
marry at a young age: 74 percent of 
married women are married before 
age 20 (IIPS and Macro International 
2007). In some states,3 more than 50 percent of women 
get married before age 18, the minimum legal age. The 
young age of marriage corresponds with early sexual 
intercourse, and with other social and health risks. Mar-
riage and first sexual experience at an early age expose 
women to a prolonged period of vulnerability to acquiring 
HIV and other STIs from their husbands. Women married 
as adolescents are also at increased risk of marital vio-
lence (see below) (Raj et al. 2010).
3These states include: the northern states of Bihar, Chattisgarh, 
Jharkhand, Madhya Pradesh, Rajasthan, Uttar Pradesh, and West Ben-
gal, and the southern state of Andhra Pradesh.
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Figure 3  HIV prevalence among HRGs in India (2008–2009)
Source: HIV sentinel surveillance, 2008–2009
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Male migration. Recent research regarding migration un-
derscores that partner migration increases women’s risk 
of acquiring HIV. A case-control study in seven districts 
with high rates of out-migration among men found that 
HIV prevalence was higher among women with migrant 
husbands. Attributable risk for women associated with 
male migration ranged from 32.7 percent to 56.9 percent 
(Saggurti et al. 2012).
Men who have sex with men and women. Research 
among men who have sex with men and women confirms 
women’s increased risk of acquiring HIV. Studies with 
men who have sex with men and women have shown that 
women are at risk of HIV acquisition due to unprotected 
sex or inconsistent condom use. (Phillips et al. 2010; 
Dandona et al. 2004). 
Intimate partner violence. Married women and female 
sex workers experiencing physical or sexual intimate part-
ner violence are at risk of acquiring and/or transmitting 
HIV infection. Violence or fear of violence may limit wom-
en’s ability to exercise choice in sexual activity and/or 
condom use. In the 2006 National Family Health Survey 
(NFHS), more than one-third of married women reported 
physical intimate partner violence from their husbands 
(IIPS and Macro International 2007). Those women 
experiencing both physical and sexual IPV were four times 
more likely to have HIV than women not experiencing 
intimate partner violence (Silverman et al. 2008). Female 
sex workers are also vulnerable to intimate partner 
violence, with a number of implications for their sexual 
and reproductive health. Female sex workers experienc-
ing intimate partner violence are at greater risk of HIV 
acquisition due to inconsistent condom use and a range 
of other reproductive health problems, including pregnan-
cy, pregnancy loss, and forced termination of pregnancy 
(Swain et al. 2011; Deering et al. 2011). 
Key Health Issues and Implications for  
Tenofovir Gel 
Contraception and dual protection. The overall contra-
ceptive prevalence rate in India is 56 percent (IIPS and 
Macro International 2007) and the vast majority of those 
using contraception use modern methods: condoms, 
injectables, intrauterine devices, male and female ster-
ilization, pills. Importantly, female sterilization accounts 
for two-thirds of total contraceptive use and 77 percent 
of modern method use (IIPS and Macro International 
2007). The widespread use of female sterilization as a 
family planning method can compromise women’s ability 
to negotiate condom use. Husbands of sterilised women 
are not likely to perceive the need for using any contra-
ceptive method, and in India there is little knowledge and 
awareness about the use of condoms as a “dual protec-
tion” method for family planning and HIV prevention. This 
underscores the need for a woman-controlled HIV-preven-
tion method like tenofovir gel. 
Maternal health. The maternal mortality rate (MMR) has 
been declining across all the regions of India in the past 
decade, but this decline has been uneven. Although MMR 
has declined in the Empowered Action Group states,4 it 
remains high (308 as of 2009). In contrast, the southern 
states’5 lower MMR of 127 as of 2009 provides hope of 
achieving the Millennium Development Goal target of 109 
(Office of Registrar General, India 2011). 
STIs and reproductive tract infections (RTIs). A 2009 
National AIDS Control Organization (NACO)-led review and 
analysis found variation in the rates of STIs/RTIs (NACO 
2009) and a considerable burden of STIs among women. 
HSV2 seropositivity (IgG) was somewhat higher in women 
compared to men in the general population (NACO 2009). 
Women’s vulnerability and increased HIV risk is evi-
denced in the epidemiology of HIV as well as indicators of 
family planning and maternal health. A woman-controlled 
HIV- prevention product such as tenofovir gel that women 
can access and use would be of value in mitigating this 
risk. 
Policy Environment
Soon after identification of the first HIV case in India in 
1986, the national government responded with policies and 
well-structured initiatives focused on generating data and 
designing programmes to address the emerging patterns 
4The Empowered Action Group states are: Assam, Bihar, Chattisgarh, 
Jharkhand, Madhya Pradesh, Odisha, Rajasthan, Uttar Pradesh, and 
Uttarakhand.
5The southern states referred to above are: Andhra Pradesh, Karnataka, 
Kerala, Tamil Nadu. 
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of the HIV epidemic in the country (NACPP 2002).6 Each 
initiative had specific objectives and strategies (NACO 2002; 
NACO and Ministry of Health and Family Welfare 2006). As 
the national programme evolved over the last two decades, 
NACO has developed several policy and operational guide-
lines, which are updated periodically and available at http://
nacoonline.org/About_NACO/Policy_Guidelines/Policies_
Guidelines1.
Since 2002, the National AIDS Control and Prevention 
Policy (NACPP) has provided overall direction and guid-
ance for HIV and AIDS programming (NACPP 2002). The 
NACPP underscores the government’s commitment to 
HIV prevention and emphasises the responsibility of both 
public and private entities. It recommends decentraliza-
tion of the HIV and AIDS control programme and supports 
integration into other national programmes. The NACPP 
seeks to decrease vulnerability to HIV among key groups 
including women and children. It underscores the need 
to provide health care to HIV-positive people and reduce 
stigma and discrimination. Strategies include promoting 
HIV knowledge and safe behavioural practices among stu-
dents, youth, and other sexually active populations, and 
voluntary blood donation to ensure safe blood supply.
The public, nongovernmental, and private sectors are 
involved in providing care, support, and treatment as well 
as preventive services. The public sector has been the 
main provider of preventive services, while the govern-
ment is receptive to the involvement of the private and 
nongovernmental sectors. The government provides a 
conducive environment for national and international 
NGOs to pilot programmatic innovations. It generally re-
quires approval from NACO consistent with public sector 
regulation of new initiatives. The public sector is generally 
open to collaboration to determine how best to integrate 
proven products and interventions into the public pro-
gramme. 
Programme and Strategy 
The National AIDS Control Programme (NACP-III), op-
erational from 2007-12, drew on lessons from earlier 
programmes and on consultations with nongovernmen-
tal and community-based stakeholders. In contrast to 
earlier programmes, it emphasised behaviour change 
6Programmes initiated included the Medium Term Plan (1990–92), the 
first plan (NACP-I, 1992–99), second plan (NACP-II, 1999–2006), and 
the NACP-III (2007–12).
rather than awareness generation, a more decentralised 
response, and increased involvement of NGOs and 
networks of people living with HIV. NACP-III aimed to halt 
and reverse the epidemic by integrating prevention with 
services providing care, support, and treatment. 
Prevention. NACP-III’s primary focus was on prevention 
given that that vast majority of people in India are HIV 
negative. Accordingly, more than two-thirds of the total 
resources were earmarked for prevention activities. The 
programme adopted a three-pronged approach to reduc-
ing the overall epidemic which prioritised saturating high-
risk groups and bridge populations with prevention mes-
sages (Ministry of Health and Family Welfare 2006). The 
programme also aimed to address clients of sex workers 
through providing condoms, social marketing campaigns, 
and projects with men in occupational settings. Finally, it 
prioritised outreach to high-risk groups in rural areas, and 
to other highly vulnerable groups: children, youth aged 
15–19, and women.
Prevention programmes were linked with care, support, 
and treatment to ensure continuity of care. Specific 
prevention services offered include targeted interventions 
for high-risk groups and bridge populations, such as nee-
dle-syringe exchange and opioid substitution therapy for 
injection drug users; prevention interventions for migrant 
populations at source, transit, and destination settings; 
and Link Worker Schemes7 for vulnerable populations 
in rural areas. Broader programmes for both high-risk 
groups and the general population include: prevention 
and control of STIs/RTIs; blood safety; HIV counseling and 
testing; prevention of parent-to-child transmission; con-
dom promotion; and information, education, and commu-
nication, and behaviour change communication. 
Care, support, and treatment. Care, support, and treat-
ment programs offer a comprehensive set of services 
despite commanding less than 20 percent of overall 
programme resources. These include: laboratory services 
for CD4 testing and other research, early infant diagnosis, 
nutritional and psychological support through Community 
Care Centres, drop-in centres for people living with HIV, 
and coordinated HIV-TB services and treatment. The pro-
gramme offers free first-line and second-line ART through 
7The Link Worker Scheme is an approach to identify and train a vil-
lage-level workforce on issues of HIV/AIDS, gender, sexuality, and STIs, 
who reach out to high risk groups and vulnerable populations in rural 
areas.
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a range of service settings (see Figure 4) includ-
ing pediatric ART and treatment of opportunistic 
infections. Tenofovir oral tablets are included 
in the regimen of first-line ART and provided 
through the service delivery system. 
Antiretroviral (ARV) service delivery. Access to 
free ART, initiated in 2004 in six high-prevalence 
states, has expanded rapidly, and second-line 
therapy is now also available in a limited number 
of ART Plus Centres. A structured service-de-
livery system aims to reduce loss-to-follow-up 
and ensure continuity of care and access to the 
entire spectrum of treatment, care, and support 
services. NACP-IV, operational through 2017, em-
phasises scaling up access to ARVs and to treat-
ment and prevention for opportunistic infections, 
as well as strengthening linkages among relevant 
service-delivery systems (NACO 2011b). 
Focus on women. Many national policies have acknowl-
edged women’s vulnerability and HIV risk, and that it 
derives from diverse factors that limit women’s access 
to health services and control in sexual decision making. 
Under NACP-III concerted efforts were made to main-
stream HIV/AIDS interventions for women’s empower-
ment, and guidelines were developed to ensure gen-
der-sensitive HIV interventions for both men and women 
(NACO 2012). 
The female condom programme, initiated in 2008, is now 
in its second phase. This programme, focused mainly 
on female sex workers, emphasises capacity building, 
training, and behaviour change communication activities 
to increase use of female condoms. After successful 
implementation in four states,8 the programme has been 
scaled up through a social marketing organization con-
tracted by NACO.
Integration of HIV with other health services. Both the 
NACP and Department of Health and Family Welfare 
(DHFW) have addressed integration of HIV and sexual 
and reproductive health. In 2010 a joint committee identi-
fied areas of convergence between NACO’s programmes 
and India’s core programme on maternal health (Ministry 
of Health and Family Welfare N.D.). The rationale was to 
leverage the technical progress of the AIDS programme 
managed by NACO and the extensive infrastructure of 
8Andhra Pradesh, Maharashtra, Tamil Nadu, and West Bengal. 
the DHFW programmes. Areas identified for convergence 
have included RTI/STI service provision, voluntary coun-
seling and testing, prevention of parent-to-child transmis-
sion, and condom promotion. While operational issues 
have limited implementation of the plan for convergence 
(Ahsan 2011), several states highlight examples of suc-
cessful integration. 
Regulatory Environment 
The Drug Controller General of India (DCGI) is the licens-
ing authority that must approve the manufacture and/or 
marketing of any new drug in India (Government of India). 
A drug approved by the DCGI must be re-registered as a 
new drug for each new route of administration (Central 
Drugs Standard Control Organization)9. This means that 
while tenofovir is approved by the DCGI as an oral tablet 
and included in first-line ART treatment in the national 
ART guidelines, the vaginal gel will need to be registered 
as a new drug and for a new indication in the Indian 
market. 
The regulations for import of new drugs10 stipulate that 
trials need to be carried out in India in accordance 
with guidelines provided by the Central Drugs Standard 
Control Organization (CDSCO)11. The DCGI can waive the 
requirement for trials in India after considering data from 
other countries. The DCGI may grant a waiver in consider-
ation of the larger public interest, or if the new drug has 
9Rule 122-Eb of the Drugs and Cosmetics Act (CDSCO N.D.)
10Rule 122-A of the Drugs and Cosmetics Act (CDSCO N.D.)
11Schedule Y (Government of India 2005)
Figure 4  Structure of ART service provision
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been approved and marketed for several years in other 
countries and the DCGI is satisfied that the published evi-
dence regarding the drug’s safety is adequate. To register 
a new drug, manufacturers have to submit an application 
to the CDSCO as per the guideline for submitting a Com-
mon Technical Document (CDSCO 2011). 
Financing 
Currently, nearly all of the overall expenditure on health 
in India comes from within the country, with an estimated 
70–75 percent from the private sector, broadly defined. 
Importantly, most of this is out-of-pocket expenditure by 
individual consumers (WHO 2012). In contrast, the gov-
ernment’s HIV programme is largely funded by external 
aid, with an estimated 69% of the most recent budget 
for the NACP coming from external sources (NACO 2012). 
At this time it is not clear whether tenofovir gel would be 
financed through the public or private sectors or both, nor 
what role external donors would play in financing procure-
ment and delivery of tenofovir gel.
Partnerships 
India’s commitment to building collective responsibility 
for HIV and AIDS programmes is demonstrated in the 
mainstreaming initiatives of NACO (NACO N.D.). Chaired 
by the Prime Minister of India, NACO includes 31 minis-
tries and departments in an effort to mainstream the pro-
gramme at national and state levels. NACO also partners 
with other sectors, including corporations and civil society 
organizations. It has a number of ongoing partnerships 
with community-based organizations and NGOs, espe-
cially those that provide targeted interventions to high-
risk groups. Recognizing the importance and long-term 
sustainability of these partnerships, NACO includes civil 
society representatives in programme and policy develop-
ment (NACO N.D.).
The most notable public–private partnership is the 
targeted Condom Social Marketing Programme involv-
ing seven social marketing organizations in 13 states. 
The programme has led to greater condom availability 
for vulnerable populations. Other partnerships with the 
private sector include workforce interventions in which 
companies provide human resources and infrastructure 
for ART centres for their employees while NACO supports 
the cost of testing facilities and drugs for the community 
(NACO N.D.). 
Looking Ahead
India is at a critical juncture in the course of its HIV epi-
demic. Although the country’s national effort and focused 
programming have begun to have an impact, many chal-
lenges remain and new ones are emerging. These include 
the increase in prevalence in particular states and the 
challenge of preventing transmission from bridge popula-
tions to the general population. The growing recognition 
of the need to reduce HIV transmission through bridge 
populations creates a potential for introducing tenofovir 
gel, as it could be used by diverse women who are vulner-
able to HIV infection. 
The current prevention programme emphasises condom 
promotion, and including female condoms among pre-
vention options is relatively new. If tenofovir gel becomes 
available, it could provide an additional option. Several 
service delivery points could be used to offer tenofovir 
gel to women if it is determined that it is appropriate and 
cost-effective in India. The extensive coverage achieved 
through targeted interventions for female sex workers 
offers a potential opportunity for delivering tenofovir gel 
in India. However, careful attention would be needed to 
ensure that introducing tenofovir gel would not under-
mine successful condom promotion efforts. The tiered 
service-delivery points in the ART structure may provide a 
setting to offer tenofovir gel to women who test negative. 
Tenofovir gel could also be offered to women at high risk 
of HIV infection, such as partners of IDUs, male migrants, 
and truckers at targeted service-delivery points. 
The policy environment in the context NACP-IV provides 
an important opportunity for promoting specific inter-
ventions that can empower women to manage their HIV 
risk. Consultative meetings with stakeholders involved in 
NACP-IV planning and implementation are an important 
venue for targeted information about vaginal HIV-preven-
tion products including tenofovir gel. Awareness gener-
ated through such efforts can ensure that policies and 
programmes are conducive to introducing tenofovir gel if 
and when its effectiveness is established.
Introduction of tenofovir gel will, however, have to over-
come certain challenges including convincing the DCGI 
of its potential benefits in a larger public health context. 
Clear findings from the ongoing FACTS 001 trial and 
approval by drug licensing authorities in other countries 
will be needed to waive the requirement for conducting 
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another trial in India. Post-approval, pilot and opera-
tional studies will also be important to understand user 
perspectives around tenofovir gel in both general popu-
lations and female sex workers. Finally, studies demon-
strating the feasibility and impact of adding tenofovir gel 
to the package of prevention services will be necessary to 
inform decision making and programming approaches. 
The overall policy context reflects that India has the polit-
ical commitment, legal environment, and administrative 
structures and guidelines to support introduction of new 
products and technologies to address the HIV epidem-
ic. It also has a proven ability to promote new products 
through social marketing partnerships. At the same time, 
the only programme exclusively focusing on women is the 
female condom programme and there has been limited 
progress in integrating HIV and reproductive health ser-
vices. Ultimately, careful analysis will be needed to weigh 
whether the challenges and costs associated with tenofo-
vir gel introduction offer sufficient benefit in the context of 
India’s HIV epidemic and response. 
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